Barriers to Effective TRAIL-Targeted Therapy of Malignancy
- 1 October 2007
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (28) , 4505-4506
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced ApoptosisClinical Cancer Research, 2007
- The promise of TRAIL—potential and risks of a novel anticancer therapyJournal of Molecular Medicine, 2007
- On the TRAIL Toward Death Receptor–Based Cancer TherapeuticsJournal of Clinical Oncology, 2007
- Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1Journal of Clinical Oncology, 2007
- Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced ApoptosisCancer Research, 2006
- TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid MalignanciesCancer Research, 2005
- mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme CellsMolecular and Cellular Biology, 2005
- Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1Cell Death & Differentiation, 2005
- Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemiaOncogene, 2002